Learn More
Mobility of users significantly impacts performance of a mobile ad-hoc network. Most existing simulation tools offer only a few random mobility models, which poorly reflect user movements in outdoor scenarios. For example, they do not consider restrictions of a spatial environment. In this paper, we describe a comprehensive and extensible approach to model(More)
MRI scans were obtained of the cervical section of the spinal cords of 30 patients with remitting multiple sclerosis. During the study period, patients received immunomodulatory agents (seven received interferon beta-1a, 13 received interferon beta-1b, and 10 received glatiramer acetate). Total focus volume in brain matter was assessed before and after(More)
Network simulation tools are frequently used to analyze performance of MANET protocols and applications. They commonly offer only simple radio propagation models that neglect obstacles of a propagation environment. In this paper, we integrate a more accurate radio propagation model into a simulation tool. The model is based on ray tracing and considers(More)
The Yaroslavl region is an endemic area for Lyme disease (LD) with one of the highest levels of morbidity in Russia. Chronic neuroborreliosis can mimic multiple sclerosis and cause considerable difficulties in differential diagnosis. A comparative clinical-instrumental analysis of patients with definite multiple sclerosis (n=65) and chronic borrelial(More)
OBJECTIVE to study safety and efficacy of the biosimilars of disease-modifying drugs (DMDs) in the prospective nonrandomized open long-term study of patients with multiple sclerosis in the Yaroslavl oblast (an Yaroslavl' cohort). MATERIAL AND METHODS The study included 203 patients treated with DMD biosimilarsduring 30 months according to the instruction(More)
Authors have followed up 230 patients with multiple sclerosis treated with disease modifying drugs (DMD) using the data of the Multiple sclerosis register of the Yaroslavl oblast during 2009-2011. Original drugs and their generics registered in Russia are used. Patients received interferon-beta 1a for intramuscular introduction (avonex - 3.0%),(More)